Medicines Formulary - search results for ""

Search results for ""

Drug name	NICE TAs	Comments	Subchapter
Peginterferon beta-1a	TA624 - Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis		8.2
Pegunigalsidase alfa (Elfabrio®)			9.8
Pembrolizumab (Keytruda®)	TA357 - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab TA366 - Pembrolizumab for advanced melanoma not previously treated with ipilimumab TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA709 - Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	For hospital use only	8.1
Pemetrexed injection	TA190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer TA181 - Pemetrexed for the first-line treatment of non-small-cell lung cancer TA135 - Pemetrexed for the treatment of malignant pleural mesothelioma TA309 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer TA124 - Pemetrexed for the treatment of non-small-cell lung cancer TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	For hospital use only. Negative TA (124)	8.1
Pemigatinib	TA722 - Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement		8.1
Penecillamine tablets		ESCA	10.1
Penicillamine		Specialist recommendation for Wilson disease. Supported with an ESCA (in development).	9.8
Penicillin 5000 units in 1ml eye drops		Unlicensed. Hospital use only, ophthalmologists.	11.3
Pentasa 1g suppositories			1.5
Pentasa M/R 500mg			1.5

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.